Dr. Morris Discusses Biomarkers in Prostate Cancer

Michael J. Morris, MD
Published: Monday, Dec 17, 2018



Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses biomarkers in prostate cancer.

Prostate cancer is a very diverse disease, says Morris, and even in the earliest stages of prostate cancer, patients need to be stratified by risk through biomarkers. From a medical oncology standpoint, biomarkers can help decide which treatment course a patient should take, and they can help indicate who is a responder and who is progressing.

There have been a number of ways in which to test patients with metastatic disease for progression, but liquid biopsies and imaging are the leading candidates, Morris says. In a poster presented at the 2018 ESMO Congress, circulating tumor-based biomarkers and PSMA-targeted imaging were compared in patients with metastatic castrate-resistant prostate cancer. This was done in an effort to determine which approach might inform the other, as well as the performance characteristics of the techniques on their own, Morris explains.
SELECTED
LANGUAGE


Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses biomarkers in prostate cancer.

Prostate cancer is a very diverse disease, says Morris, and even in the earliest stages of prostate cancer, patients need to be stratified by risk through biomarkers. From a medical oncology standpoint, biomarkers can help decide which treatment course a patient should take, and they can help indicate who is a responder and who is progressing.

There have been a number of ways in which to test patients with metastatic disease for progression, but liquid biopsies and imaging are the leading candidates, Morris says. In a poster presented at the 2018 ESMO Congress, circulating tumor-based biomarkers and PSMA-targeted imaging were compared in patients with metastatic castrate-resistant prostate cancer. This was done in an effort to determine which approach might inform the other, as well as the performance characteristics of the techniques on their own, Morris explains.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x